Pharmaceutical compositions containing amylin

• US 5,124,314 A
• Filed: 06/10/1991
• Issued: 06/23/1992
• Est. Priority Date: 08/26/1987
• Status: Expired due to Term

• Current Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Cooper, Garth J. S.
• Primary Examiner(s): LEE, LESTER
• Application Number:
  US07/715,031
• Time in Patent Office: 379 Days
• Field of Search: 514/3-4, 514/12-17
• US Class Current: 514/6.4
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 33/30 Zinc; Compounds thereof
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/225 Calcitonin gene related peptide
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 5/48 of the pancreatic hormones
• CPC Class Codes: C07K 14/575 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695

Abstract

The present invention relates to pharmaceutical compositions for use in treating diabetes Mellitus or hypoglycemia containing Amylin as the effective additive.

Claims

1. A pharmaceutical composition for use in the treatment of diabetes mellitus or hypoglycemia which comprises a therapeutically effective amount of amylin in association with a pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 1 wherein said composition is lyophilized.

5. The pharmaceutical composition of claim 1 wherein said composition is disposed in a vehicle suitable for delayed-release administration.

7. The pharmaceutical composition of claim 1 which comprises a suspension of said amylin, said suspension being formulated with a zinc salt in a pharmaceutically acceptable buffer, and said suspension being suitable for parenteral administration.

9. The pharmaceutical composition of any of claims 1-7 or 8 wherein said amylin is human amylin.

2. A pharmaceutical composition for use in the treatment of diabetes mellitus or hypoglycemia which comprises therapeutically effective amount of amylin and a therapeutically effective amount of an insulin in association with a pharmaceutically acceptable carrier.

4. The pharmaceutical composition of claim 2 wherein said composition is lyophilized.

6. The pharmaceutical composition of claim 2 wherein said composition is disposed in a vehicle suitable for delayed-release administration.

8. The pharmaceutical composition of claim 2 which comprises a suspension of said amylin and said insulin, said suspension being formulated with a zinc salt in a pharmaceutically acceptable buffer, and said suspension being suitable for parenteral administration.